Pathophysiological study of atorvastatin drug on toxicity induced by D-galactose in liver of experimental rats

Sadiq Sh. A.
Department of Biology, College of Science, University of Basrah, Basrah, Iraq.
Email: pgs2078@uobasrah.edu.iq

Ikbal A. H.
Department of Biology, College of Science, University of Basrah, Basrah, Iraq.
Email: eqbal.hazam@uobasrah.edu.iq

Kassim F. A.
Department of Clinical Laboratory Sciences, College of Pharmacy, University of Basrah, Basrah, Iraq.
Email: kassim.Kareem@uobasrah.edu.iq

Abstract---Background: This study was designed to clarify the toxic effect of a high dose of atorvastatin and the palliative effect of low doses of atorvastatin on toxicity induced by D-galactose in the liver, kidney, and adrenal gland organs. The current study was conducted on 36 healthy adult male Wistar albino rats (Rattus norvegicus) who were sexually mature at the age of 8-10 weeks and weighed between 200 and 250 grams in the animal house of Pharmacy College/ Basrah University. Methods: These rats were selected and divided into six main groups of equal weight, each with six rats. The first group (control) was drenched in (1) mL of normal saline. The second group was drenched in a single dose of atorvastatin (150 mg per kg B.W), the third received D-galactose at a dose of (500 mg per kg B.W), and the fourth group was treated with both D-galactose and atorvastatin (10 mg per kg B.W), the fifth group was coadministered with both D-galactose and atorvastatin (20 mg per kg B.W), and the sixth group where rats cotreated with Dgalactose and atorvastatin (40 mg per kg B.W). The treatment was extended for 8 weeks. At the end of the experiment, all groups were sacrificed, and blood was isolated to measure biochemical tests such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and total bilirubin. To prepare for histological examination, the liver was fixed in formalin solution. Results and discussion: The result of biochemical tests revealed: Significant increase in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin in both high-dose
atorvastatin and D-galactose treated rats compared with a control group. On other hand, animals cotreated with D-galactose and 10,20, and 40 mg per kg single dose of atorvastatin showed a significant decrease in ALT, AST, and total bilirubin compared with D-galactose treated group. The histological study revealed many pathological changes of different degrees in the liver in all treated animal groups: High dose atorvastatin 150 mg per kg group treated group showed necrotic hepatocyte and fat degeneration. White D-galactose coadministered rats exhibited liver congestion of the central vein and inflammation. Male rat’s livers cotreated with D-galactose and 10,20,40 mg per kg atorvastatin revealed less necrosis with mild fat degeneration compared with histological changes noted in the D-galactose group and high dose of atorvastatin.

Keywords---Atorvastatin Drug, Toxicity in Liver, D-galactose.

I. Introduction

Statins, or inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are widely used to lower serum cholesterol levels and reduce long-term morbidity and death associated with coronary artery disease. In most animal species and humans, statins are quite efficient at lowering serum cholesterol (Sahebkar et al., 2016). Statins may have non–lipid-related pleiotropic effects in addition to lowering low-density lipoprotein cholesterol and cardiovascular morbidity and death. Endothelial function is improved, atherosclerotic plaques are stabilized, anti-inflammatory, immunomodulatory, and antithrombotic effects are present, as are benefits on bone metabolism and a reduced risk of dementia. The suppression of the production of isoprenoid intermediates in the mevalonate pathway is assumed to be the source of these extra advantages (Ward et al., 2019). Furthermore, statin use has been shown to lower pro-inflammatory mediator production, protect cells from oxidative damage during vascular injury, decrease platelet adhesion, activation, and thrombin generation, and improve blood flow (Jiang & Zheng, 2019). Among the statins is Atorvastatin, a synthetic 3-hydroxy-3-methylglutaryl coenzyme A analog with a significant effect in lowering total and low-density lipoprotein cholesterol levels, triglycerides, and changing the makeup of lipoproteins (Huisa et al., 2010). Atorvastatin inhibits the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, which creates mevalonate in hepatic tissue. Mevalonate is a chemical that aids in the production of cholesterol. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition reduces cholesterol production, lowering low-density lipoprotein cholesterol levels in the blood (Jabir & Jaffat, 2018). Other well-known qualities of Atorvastatin include anti-oxidant, anti-aging, anti-inflammatory, and analgesic actions (Taghipour et al., 2019). Other statin side effects include neurological and neurocognitive consequences, hepatotoxicity, renal toxicity, and others (gastrointestinal, urogenital, reproductive), many of which are currently unknown (Ward et al., 2019). The most prevalent hepatic adverse effects linked with atorvastatin are asymptomatic hepatic enzyme increases (Bhardwaj, 2007). D-galactose is an important nutrient and a reducing sugar that reacts with amino acids to form advanced substances associated with glycosylation. Its injection in high doses contributes to the generation of reactive
oxygen species via its metabolism by galactose oxidase to hydrogen peroxide, eventually generating reactive oxygen species, as well as altering the normal osmotic pressure, which leads to metabolic disorders of vital organs and eventually organism aging (Saleh et al., 2019).

II. Materials and Methods

Experimental Animals

The experiments were conducted in the animal house of Pharmacy College, University of Basrah, using (36) healthy adult male Wistar albino rats (Rattus norvegicus) which were sexually mature at the age of (8-10) weeks and weighed between (200) and (250) grams. The animals were housed in plastic cages with mesh tops that measured (20×30×40) cm and were kept at a comfortable temperature of (20-30°C) with a 12-hour light/dark cycle. Before beginning the experiment, they were acclimatized for (3) weeks in plastic cages with sanitary beds, (6) rats per cage. Throughout the experiment, all rats were fed standard laboratory pellets and were given fresh clean water ad libitum (Salman, 2021).

Preparation of Drugs

The appropriate amount and doses were prepared using Atorvastatin tablets and D-galactose stock powder according to the following formula: \((C_1 V_1 = C_2 V_2)\) C stands for concentration, while V stands for volume. According to Taghipour et al., (2019), D-galactose doses of (500) mg per kg body weight were prepared by dissolving (625) mg of D-galactose powder in (6) ml of normal saline to obtain (104) mg of D-galactose in each 1 ml of prepared solution. An electric grinder was used to ground atorvastatin tablets to a fine powder. Following that, daily doses were weighed using analytical balances. These doses were dissolved in normal saline daily over the experimental period, and gavage was used to administer the medicines to the rats orally. Atorvastatin at dose (10) & (20) mg per kg, single dose per body weight depended on (Panonnummal et al., 2014). Atorvastatin dose (40) mg per kg, single dose per body weight depended on (Jiang & Zheng, 2019). Atorvastatin dose (150) mg per kg, single dose per body weight depended on (Reddy et al., 2010).

Experimental Design

Thirty-six adult male rats were chosen and divided into six groups of equal weight, with six rats in each group, as follows:

1. The First (Control) Group: They were given (1) ml of normal saline through a stomach tube for two months as a negative control.
2. The Second (Atorvastatin 150 mg / kg) Group: This group was administered orally with (1) ml of a hazardous dose of (150) mg per kg, single dose per body weight of atorvastatin for two months as a positive control.
3. The Third (D-galactose 500 mg / kg) Group: This group was administered orally with (1) ml of a hazardous dose of (500) mg per kg, single dose per body weight of D-galactose for two months as a positive control.
4. The Fourth (10 mg / kg atorvastatin & D-galactose) Group: This group was administered orally both of (1) ml Atorvastatin with a dose of (10) mg per kg,
single dose per body weight and (1) ml D-galactose with a dose of (500) mg per kg, single dose per body weight, for two months.
5. The Fifth (20 mg / kg atorvastatin & D-galactose) Group: This group was administered orally both of (1) ml Atorvastatin with a dose of (20) mg per kg, single dose per body weight and (1) ml D-galactose with a dose of (500) mg per kg, single dose per body weight, for two months.
6. The Sixth (40 mg / kg atorvastatin & D-galactose) Group: This group was administered orally both of (1) ml Atorvastatin with a dose of (40) mg per kg, single dose per body weight and (1) ml D-galactose with a dose of (500) mg per kg, single dose per body weight, for two months.

Sample Collection: Collection of Blood Samples

At the end of the eight-week experiment period, all rats in all experimental groups were sacrificed. Following a chloroform anesthesia, an appropriate cut in the rat abdomen was made. The blood samples were obtained from the heart using disposable syringes with a volume of (3-5) cc. (5) ml of blood was placed into jelly test tubes free of anticoagulant and centrifuged at 3500 rpm for (10) minutes to isolate blood serum, which was then transferred to eppendorf tubes and stored at -20 °C. (Cray et al. 2009). Biochemical parameters such as liver enzymes alanine aminotransferase and aspartate aminotransferase, total bilirubin, are all measured in blood serum.

Collection of Tissue Samples

At the end of the eight-week experiment, liver from rats in each experimental group were dissected, washed with normal saline to remove blood and tissue debris, then cut into appropriate sizes and transferred to be fixed with formalin (10%) to be ready for histological study. (luna, 1968).

III. Results

Biochemical Results: Effects of D-galactose, Atorvastatin Alone, Combination of D-galactose with Different Doses of Atorvastatin on Liver Enzymes

The obtained results in (Table 1) reveal significant (P≤0.05) increase of both AST and ALT in serum of male rats treated with D-galactose and atorvastatin at (150 mg per kg) dose compared with control group and other groups. Both AST and ALT in serum of rats coadministration with both D-galactose and different doses of atorvastatin (10, 20, 40 mg per kg) showed significant (P≤0.05) decrease in comparison with D-galactose group.

Effects of D-galactose, Atorvastatin, Combination of D-galactose with Different Doses of Atorvastatin on Total Bilirubin Concentration

Results in (Table 2) reveal significant (P≤0.05) increase in total bilirubin concentration in both D-galactose group and high dose atorvastatin group compared with control group. Total bilirubin concentration in serum of rats
treated with both D- galactose and atorvastatin drug at dose (20, 40 mg per kg) exhibited significant \((P \leq 0.05)\) decrease compared with D- galactose group.

Table 1: Effects of D-galactose, Atorvastatin Alone, Combination of D-galactose with Different Doses of Atorvastatin on Liver Enzymes: (Mean ± Standard Deviation)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ALT Mean ± Sd</th>
<th>AST Mean ± Sd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control Group</td>
<td>29.9667 ± 2.26</td>
<td>108.7333 ± 4.88</td>
</tr>
<tr>
<td>Atorvastatin 150 mg/kg Group</td>
<td>35.2000 ± 0.22</td>
<td>131.6967 ± 0.75</td>
</tr>
<tr>
<td>D-galactose 500 mg/kg Group</td>
<td>36.7167 ± 0.51</td>
<td>170.3100 ± 0.81</td>
</tr>
<tr>
<td>Atorvastatin-D-galactose 500 mg/kg Group</td>
<td>30.3400 ± 0.07</td>
<td>167.6067 ± 0</td>
</tr>
<tr>
<td>Atorvastatin-D-galactose 500 mg/kg Group</td>
<td>27.0000 ± 3.28</td>
<td>150.0000 ± 0</td>
</tr>
<tr>
<td>Atorvastatin-D-galactose 500 mg/kg Group</td>
<td>27.6733 ± 0.40</td>
<td>140.7633 ± 0</td>
</tr>
<tr>
<td>LSD</td>
<td>2.98</td>
<td>6.71</td>
</tr>
</tbody>
</table>

Different letters indicate significant differences among experimental groups at \((P \leq 0.05)\).
Table 2: Effects of D-galactose, Atorvastatin, Combination of D-galactose with Different Doses of Atorvastatin on Total Bilirubin concentration: (Mean ± Standard Deviation)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean ± standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control Group</td>
<td>0.6333 ± 0.21 b</td>
</tr>
<tr>
<td>Atorvastatin 150 mg./kg. Group</td>
<td>2.1667 ± 0.06 a</td>
</tr>
<tr>
<td>D-galactose 500 mg./kg. Group</td>
<td>1.7000 ± 0.87 ab</td>
</tr>
<tr>
<td>Atorvastatin 10 mg./kg. + D-galactose 500 mg./kg.</td>
<td>1.2667 ± 0.29 b</td>
</tr>
<tr>
<td>Atorvastatin 20 mg./kg. + D-galactose 500 mg./kg.</td>
<td>0.7000 ± 0.00 b</td>
</tr>
<tr>
<td>Atorvastatin 40 mg./kg. + D-galactose 500 mg./kg.</td>
<td>0.9667 ± 0.23 b</td>
</tr>
<tr>
<td>LSD</td>
<td>0.71</td>
</tr>
</tbody>
</table>

Different letters indicate significant differences among experimental groups at (P≤0.05).

**Histopathological Results**

The liver of Control male rats showed polygonal lobules with central vein and radiating hepatocellular trabeculae enclosing liver sinusoids and hepatocytes. Portal triad composed of bile ductile, portal venule and arteriole appeared at the periphery of the lobules. Hepatocytes showed eosinophilic cytoplasm with large central nuclei and small hyperchromatic nucleoli. No inflammatory cells, no fibrous connective tissue were observed (Figure 1). Liver tissue in male rats treated with high dose of atorvastatin showed well preserved Lobular architecture, with dilated central vein. Many hepatocytes are necrotic with aggregates of inflammatory cells and areas of fat degeneration. Hepatocytes revealed enlarged nuclei with large, occasionally multiple prominent and eosinophilic nucleoli. Sinusoids are not visualized because of congestion (Figure 2). Liver in male rats treated with D-galactose appear ant fatty degeneration, dilated, congested central veins, many hepatocellular are necrotic, with increased inflammatory cells. Portal veins and sinusoids appeared dilated and congested (Figure 3). The liver of male rats cotreated with both D-galactose and (10 mg per kg) atorvastatin showed dilated central vein. Mild cell necrosis, atypical nuclei, occasional fat necrosis, bile ducts hypertrophied. Sinusoids appeared normal. No inflammation was observed (Figure 4). Male rats' livers treated with D-galactose and (20 mg per kg) atorvastatin were similar to rats' livers treated with D-galactose and (10 mg per kg) atorvastatin, but necrosis was less or absent. Histology of the liver is almost normal (Figure 5). Liver in male rats cotreated with D-galactose and (40 mg per kg) atorvastatin revealed mild hepatocellular necrosis, congested central vein with mild fat degeneration and inflammatory infiltrate at portal area. Bile ducts are normal (Figure 6).
Fig. 1. cross section in liver showing:
- a: central vein.
- b: trabeculae enclosing.
- c: sinusoids. in control group.

Fig. 2. cross section in liver showing:
- a: necrotic.
- b: degeneration. in high dose of atorvastatin group.

Fig. 3. cross section in liver showing:

Fig. 4. cross section in liver showing:
- a: fatty degeneration.
- b: necrotic.
- a: mild cell necrosis.
- b: atypical nuclei. in D-galactose group. in both D-galactose and (10 mg per kg) atorvastatin group.
Fig. 5. cross section in liver showing: a: central vein. b: sinusoids appear normal. In both D-galactose and (20 mg per kg) atorvastatin group.

Fig. 6. cross section in liver showing: a: mild hepatocellular necrosis. b: central vein congested. In both D-galactose and (40 mg per kg) atorvastatin group.

IV. Discussion

Biochemical Results: Effects of D-galactose, Atorvastatin Alone, Combination of D-galactose with Different Doses of Atorvastatin (10, 20, 40 mg per kg) on Liver Enzymes

The results of current study show a significant (P≤0.05) increase in both AST and ALT enzymes in D-galactose treated rats compared to control group and other treated rats which agrees with the study of Gao et al. (2018) who confirmed that overload of d-galactose can increase the production of reactive oxygen species, resulting in oxidative stress that can attack essential cell constituents, induce lipid peroxidation, damage the membranes of cells and organelles in the liver, cause the swelling and necrosis of hepatocytes, and ultimately result in hepatic injury. Our present study is consistent with the study of Badebustan et al. (2019) who observed lipid oxidation in liver, as well as an increase in AST and ALT after D-galactose ingestion. When compared to normal rats, D-galactose causes considerable increases in the liver enzyme biomarkers ALT, AST, total bilirubin, and direct bilirubin. D-galactose-induced increases in liver aminotransferases have been identified as early sensitive markers of liver injury during liver aging (Chen et al., 2018; El-Baz, et al., 2018). In agreement with the results of our current study, increased ALP, AST, and ALT levels indicate that the liver is releasing these enzymes into the bloodstream, indicating hepatotoxicity, liver tissue damage, and liver necrosis (Hu et al., 2014). Hepatocytes ordinarily contain the enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), and their levels in the blood are usually related to the severity of the liver injury. The activity of these enzymes rises when the liver is inflamed or dysfunctional. ALT, AST, and ALP levels in the serum and liver of animals treated with D-galactose were found to be significantly elevated in previous studies (Chen et al., 2011, 2018; Huang et al., 2013; Kong et al., 2018; Lin et al., 2018; Liu et al., 2019; Mo et al., 2017; Mohammadi et al. 2018; Shahrourdi et al. 2017; Taghipour et al., 2019; Wang et al., 2018; Yang et al.,...
However, our results reveal that coadministration of atorvastatin 10, 20, and 40 mg per kg with Dgalactose reduce the toxic effects of D-galactose on hepatocytes by a decrease in both ALT and AST. This agrees with the study of Taghipour et al., (2019) who showed that atorvastatin treatment could improve renal and hepatic toxicity induced by D-galactose and regulate ALT, and AST levels in mice. Several studies showed non-alcoholic fatty liver disease patients prescribed statins in before-after interventional studies had a reduction of baseline values for all safety outcomes analyzed, such as ALT and AST, and that the results of the meta-analysis provide pooled data on the safety of statin treatment in patients with non-alcoholic fatty liver disease. The findings add to previous evidence from a retrospective study involving 4024 hyperlipidemia patients, which showed no increased risk of hepatotoxicity in statin-treated patients, reinforcing the evidence that statin therapy may be safe in Non-alcoholic fatty liver disease patients even when liver damage is almost clinically evident (Daniele et al., 2021). Even if serum liver enzymes are mildly elevated, clinicians should not be discouraged from prescribing statins to non-alcoholic fatty liver disease patients. Indeed, a clinically significant druginduced liver injury by statins is very rare (Einar et al., 2012). Our results show that a high dose of atorvastatin caused an elevation in ALT and AST levels which agrees with Jiang & Zheng (2019) who showed that rats administered atorvastatin at a dose of 80 mg per kg daily exhibited higher levels of AST and ALT, and is consistent with the study of Abed Al-kareem et al., (2020) who observed a significant increase in ALT and AST concentration in albino rats administered atorvastatin for 60 days as many drugs overdoses cause liver injury and elevate levels of liver enzymes biomarkers. Most drug-induced liver injuries induced by statins are a consequence of the idiosyncratic effect. Nevertheless, as most of the statins are metabolized by CYP3A4, the concomitant use of a drug inhibiting CYP3A4 could elevate serum concentration of atorvastatin, simvastatin, and lovastatin and may favor liver enzyme elevation (Karahalil et al., 2017).

Biochemical Results: Effects of D-galactose, Atorvastatin, Combination of Dgalactose with Different Doses of Atorvastatin (10,20,40 mg per kg) on Total Bilirubin concentration

Our present study reveals a significant increase in total bilirubin concentration in D-galactose treated rats which coincides with the study of Chen et al., (2018) and El-Baz, et al., (2018) who noticed that D-galactose treated rats showed considerable increases in liver enzyme biomarkers AST and ALT, and total bilirubin and direct bilirubin. Furthermore, D-galactose significantly raised serum total and direct bilirubin in rat sera. Because bilirubin catabolism is dependent on liver functions, elevated bilirubin levels indicate hepatocellular dysfunction (Boland et al., 2014). In addition, higher direct bilirubin in D-galactose-treated rats implies not only hepatic dysfunction but also reduced intrahepatic excretion of conjugated bilirubin from bile duct hepatocytes (Astegiano et al., 2004). Bilirubin is a mediator of (Heme oxygenase-1-mediated) cytoprotection against oxidative stress and intracellular homeostasis balance (Gomes et al., 2010). This could explain why bilirubin levels in rats exposed to Dgalactose and other oxidative stress stimuli rose (Nam et al., 2018; Roller et al., 2010). Following D-galactose treatment, several studies found a decrease in antioxidant defense machinery and an increase in oxidative stress indicators (Coban et al., 2014; El-
In addition, Machova et al., (2007) explained that atorvastatin therapy led to an elevation in total bilirubin concentration in mice after three weeks, which agrees with our recent findings indicating that rats treated with a high dose of atorvastatin exhibited an elevated level of total bilirubin. Statins' long-term effect on bilirubin levels in people is unknown. In a randomized trial, pravastatin treatment was related to a decreased serum total bilirubin level after one year compared to the control group in patients with advanced hepatocellular carcinoma (Kawata et al., 2001).

Histopathological Results: Effects of high dose Atorvastatin, D-galactose, Combination of D-galactose with Different Doses of Atorvastatin (10,20,40 mg per kg) on Liver

The onslaught of reactive oxygen species on the liver causes it to gradually deteriorate with age. Because D-galactose is primarily processed in the liver, a high level of D-galactose in the body might hurt the liver. Treatment with D-galactose has been shown to cause oxidative stress in the liver by increasing Nitric oxide, malondialdehyde, and 8-hydroxy-2-deoxyguanosine while decreasing Catalase, glutathione peroxidase, superoxide dismutase, nitric oxide synthase, reduced glutathione, and total antioxidant capacity in liver tissues (Chen et al., 2011, 2018; Feng et al., 2016; Ji et al., 2017; Kong et al., 2018; Lei et al., 2016; Li et al., 2005; Liu et al., 2018; Mo et al., 2017; Mohammadi et al., 2018; Noureen et al., 2019; Shahrudi et al., 2017; Xu et al., 2016; Yang et al., 2019; Zhuang et al., 2017). The intracellular (p38 mitogen-activated protein kinasenuclear factor erythroid 2-heme oxygenase-1) (p38 MAPK-NRF2-HO-1) signaling pathway in the liver has been shown to activate by D-galactose therapy (Gao et al., 2018; Lin et al., 2018). Through the p-p38 mitogen-activated protein kinase (p-p38 MAPK) pathway, a surplus of D-galactose resulted in an accumulation of galactose and its final metabolite galactitol, which finally led to cell osmotic stress and the accumulation of reactive oxygen species (Gao et al., 2018). D-galactose therapy was proven to cause an inflammatory response when combined with oxidative stress, in animals liver issues treated with D-galactose exhibited an increase in inflammatory markers such as tumor necrosis factor-alpha (TNF-), interleukin 6 (IL-6), nuclear factor kappa beta (NF-B), inducible nitric oxide synthase (iNOS), and COX-2 inhibitors (COX2) (Feng et al., 2016; Huang et al., 2013; Ji et al., 2017; Liu et al., 2018). Therapy with D-galactose significantly increased the expression levels of apoptotic proteins in liver tissues when compared to the control group, including B-cell lymphoma-2-associated X protein, procaspase-3, caspase-3, and the ratio of B-cell lymphoma-2 to B cell lymphoma2-associated X protein (Chen et al., 2018; Gao et al., 2018; Shahrudi et al., 2017; Xu et al., 2016). Furthermore, when compared to the control group, the liver index of the D-galactose-treated mice was significantly lower (Gao et al., 2018; Liu et al., 2019). Reduced liver index translates to a lower liver coefficient, which is the result of the D-galactose treatment. Treatment with D-galactose can harm the liver structurally and histologically. The hepatocyte arrangement was shown to be chaotic in D-galactose-treated mice, whereas the hepatic cords were organized loosely with sinusoid dilatation (Liu et al., 2019; Huang et al., 2013). Pathological damage to the hepatocytes included an increase in intercellular space and ballooning degeneration (Lin et al., 2018; Wang et al., 2018; Zhuang et al., 2017). The sizes of the cell nuclei in the liver varied, and some were dissolved (Liu et al., 2019).
The hepatocytes showed swelling, the cytoplasm was vacuolar and loose, the central veins congestive and dilated, and parts of the hepatocytes showed eosinophilic changes (Gao et al., 2018). The swollen hepatocytes led to the intrusion of lymphocytes and inflammatory cells (Chen et al., 2018; Gao et al., 2018; Ji et al., 2017; Liu et al., 2019; Taghipour et al., 2019; Zhuang et al., 2017). Necrosis, pyknosis, fibrosis, central vein congestion, fat deposit, and apoptosis other damages were also seen in the hepatocytes. (Chen et al., 2018; Feng et al., 2016; Huang et al., 2013; Ji et al., 2017; Liu et al., 2019; Taghipour et al., 2019; Zhuang et al., 2017). Some of the histomorphological damages observed in the livers of D-galactose-treated rats were similar to those observed in the naturally aged control. The livers of the D-galactose-treated rats showed some different other changes and an expression in hepatic-protein increased (Huang et al., 2013; Wang et al., 2018). D-galactose-treated animals had lower glycogen levels and greater lipid accumulation in their livers than the control animals (Wang et al., 2018). All of these previous studies support our findings that the D-galactosetreated group’s liver tissue suffers from fatty degeneration and necrosis. And the use of atorvastatin at doses of 10, 20, and 40 mg per kg in combination with Dgalactose reduces these histological lesions. Another study by Mustafa & Abdullah (2019) found that atorvastatin caused focal lymphocyte accumulation and cytoplasmic vacuolization in the liver of male albino rats.

V. Conclusions

The current study concludes the following: D-galactose and atorvastatin at toxic doses raise liver biomarkers like AST, ALT, and bilirubin. Hepatotoxicity can be reduced by taking atorvastatin at doses of 10, 20, and 40 mg per kg of body weight. D-galactose and atorvastatin at 150 mg per kg body weight induce histological changes in the liver. The most effective and potent dose of atorvastatin to alleviate Hepatotoxicity is 20 mg per kg.

References


Daniele Pastori; Arianna Pani; Arianna Di Rocco; Danilo Menichelli; Gianluca Gazzaniga; Alessio Farcomeni; Laura D’Erasmo; Francesco Angelico; Maria Del Ben; Francesco Baratta; (2021). Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.14943


